Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.31 |
| ▸ | HMGCR | P04035 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919332 | 1.00 | TOP2A (0.31) | TOP2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4899890 | 0.83 | PDE4D (0.34) | TOP2A | |
| SCHEMBL7493619 | 0.83 | PDE4D (0.34) | TOP2A | |
| SCHEMBL4919329 | 0.78 | HMGCR (0.30) | HMGCR | |
| SCHEMBL782454 | 0.77 | TAAR1 (0.34) | — | |
| SCHEMBL782455 | 0.77 | TAAR1 (0.34) | — | |
| SCHEMBL4895625 | 0.77 | — | — | |
| SCHEMBL4893196 | 0.76 | CTSL (0.37) | SIGMAR1 | |
| SCHEMBL14107808 | 0.76 | CTSL (0.37) | SIGMAR1 | |
| SCHEMBL724384 | 0.75 | NAAA (0.41) | TOP2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | STICHTING REGA VZW (BE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176813-A1 | CARBOCYCLIC NUCLEOSIDES AND PROCESS FOR OBTAINING SUCH | ATIC, ADORA2A, ADORA3 | TOP2A 203/4885PSEN1 4692/4885PSEN2 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.